HOME >> MEDICINE >> NEWS
First US kidney cancer vaccine trial underway at Columbia

The first U.S. kidney cancer vaccine trial is now underway at Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia. While the potential for vaccines to treat solid tumors has been recognized for more than a decade, this trial is pioneering the use of tumor immunotherapy boosting the body's natural immune system as a way to fight cancer.

"Vaccines are an exciting prospect in cancer treatment and this trial is an example of our program's dedication to bringing the latest advances in tumor vaccines and immunotherapy to patients with cancer," said Howard L. Kaufman, M.D., associate professor of surgery and pathology at Columbia University Medical Center and director, Tumor Immunotherapy Program at NewYork-Presbyterian/Columbia. "We expect that combining IL-2 with Trovax will double the treatment response rate for our kidney cancer patients, offering new hope for these patients."

Vaccines, usually associated with the prevention of infectious diseases, e.g., measles, help the body's immune system recognize and kill foreign invading organisms. Recent research has provided evidence that vaccines may also be useful for preventing or treating cancer. Tumor vaccines contain a specific protein of the tumor cell that stimulates an immune response.

In the study, patients with stage IV renal cell carcinoma are given regular doses of an investigational kidney cancer vaccine, called Trovax, in conjunction with Interleukin-2 (IL-2). High-dose IL-2 is currently the only approved treatment for kidney cancer, and Columbia University Medical Center and New York-Presbyterian Hospital/Columbia are the only site in New York to offer IL-2. Kidney cancer is one of the few cancers for which chemotherapies are not effective treatments.

A small protein (cytokine) naturally produced by the cells of the immune system, IL-2 stimulates T-cells, which are activated in an immune response system and create tumor killing cells. The
'"/>

Contact: Elizabeth Streich
eas2125@columbia.edu
212-305-6535
Columbia University Medical Center
27-Jan-2005


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
6. First blood test to diagnose paralyzing, blinding disease
7. First US SARS vaccine trial opens at NIH
8. First-ever safety study of medical cannabis use in Canada launched
9. First solid evidence that the study of music promotes intellectual development
10. First medical test on CD gets good results
11. First proof that cutting Rx drugs due to cost harms health

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology:
Cached News: